RETURN TO WORK WITH CONFIDENCE. SPEAK TO US TO SEE HOW WE CAN SUPPORT YOU. READ OUR COVID-19 POLICY here.

Perspectum Diagnostics

December 7th 2016

How one Oxford based medical company is expanding with new UK and US offices.

Following significant business growth, Perspectum Diagnostics, the company behind a revolutionary new medical device that removes the need for costly and painful liver biopsies, is set to graduate from serviced offices at Oxford Centre for Innovation to fully leased offices at Beaver House, Hythe Bridge Street, Oxford. The University of Oxford spin-out has more than tripled its headcount in addition to opening two US offices in the last two years due to the success of its LiverMultiScan, a new way of assessing disease in the liver by measuring the amount of fat, iron, fibrosis and inflammation of the liver in the same scan.

“Oxford Innovation has played an important role in our success. Through being based at OCFI we were automatically surrounded by other technology and medical organisations as the set-up appeals to people in similar industries. When we first moved to OCFI we were at an early phase of innovation but we have been able to grow within the centre avoiding costly overheads and are now ready to graduate into our own offices.”

 

Dr. Rajarshi Banerjee, CEO of Perspectum Diagnostics

To facilitate the company’s rapid growth, vital business support has been provided from Oxford Innovation Services via Enterprise Europe Network (EEN) advisors, leading to the award of two major grants totalling €4.5million in addition to providing Perspectum Diagnostics with market data assisting with international expansion. Perspectum’s LiverMultiScan device is currently under consideration by the National Institute for Health and Care Excellence (NICE) for adoption by the NHS for liver diagnosis, which could lead to significant savings of £500 per patient for a disease that currently effects 15 – 20 per cent of the UK’s population.

June 29th 2021

Five minutes with David Llewellyn from DJS Antibodies

A dynamic new biotech started by Dr David Llewellyn and Dr Joe Illingworth, DJS Antibodies is pioneering the development of novel therapeutics to treat the world’s most critical inflammatory diseases, a class of disease that accounts for more than 50% of deaths worldwide.

June 4th 2021

Five minutes with Peter Hamley from Samsara Therapeutics

We spoke to Peter Hamley, Chief Scientific Officer of amazing biotech start-up Samsara Therapeutics, who have just moved into the new life science labs at our Wood Centre for Innovation.

May 5th 2021

Five minutes with Adam Forsyth, CTO of TZ

We spoke to Adam Forsyth CTO of TZ, an Australian start-up at the forefront of electronic locking device development and one of our newer residents at the Oxford Centre for Innovation.